CA-ATLASSIAN
Atlassian , a leading provider of collaboration software for teams, today announced Atlassian Connect - an extensible new framework for developers to build add-ons that deeply integrate with Atlassian JIRA OnDemand and Atlassian Confluence OnDemand, the company's cloud-based issue tracking and collaboration offerings. Developers can offer these add-ons to Atlassian's 33,000 customers via the Atlassian Marketplace , a proven ecosystem of more than 1,500 commercial and free add-ons. Since the Atlassian Marketplace launched in 2012, third party add-on developers who have sold products via the platform have earned more than $20 million.
"Customer demand for customized add-ons to our cloud-based JIRA and Confluence offerings has been incredible," said Nick Wade, director of Atlassian Marketplace. "With our next generation development framework – Atlassian Connect – third-party developers can now easily create secure and scalable add-ons for millions of Atlassian cloud-based customers and sell their products via our marketplace. We’re thrilled to help fellow developers build their own businesses."
Click to tweet : "Announcing @Atlassian Connect, the next generation of add-ons for No. JIRA and No. Confluence OnDemand http://ow.ly/ucD4I"
The new Atlassian Connect framework, built on common web standards like REST APIs and JWT authentication, offers additional modules for developers to integrate add-ons directly into Atlassian applications using the technology stack of their choice. Third-party partners like Zendesk, Lucidchart, Gliffy, Zephyr, and Comalatech are among the early adopters of Atlassian Connect. Today 15 publicly available add-ons for Atlassian JIRA and Confluence OnDemand are already in use by more than 600 companies.
"The streamlined discovery and procurement experience offered by marketplaces accelerates the consumption of applications - making it a win/win for both customer and developer, as the mobile market has more than adequately demonstrated," said Stephen O'Grady, principal analyst with RedMonk. "Atlassian has invested heavily in this area, and with Atlassian Connect is attempting to dramatically expand the reach of its Marketplace to the cloud."
"We see Atlassian Connect as an opportunity to re-architect our successful diagramming and mockup tool for JIRA," said Chris Kohlhardt, CEO of Gliffy. "Based on Atlassian Connect, the next version of Gliffy for JIRA OnDemand will maintain the same intuitive interface and we'll be able to deploy product improvements instantly."
Rich platform for developers
Atlassian Connect provides rich user interface integration and continuous two-way communication to create smoother end-to-end experiences for customers. Specifically, Atlassian Connect offers:
- Simple descriptors: Any web application – written in any language – can become an Atlassian Connect add-on by providing a simple JSON file to describe itself to Atlassian applications. Atlassian has already built client libraries for node.js and the Play framework to make getting started even easier.
- User interface modules: Atlassian Connect provides almost two dozen different UI integration points, such as issue panels, page macros, and fullscreen pages for add-ons to insert content directly into the Atlassian application.
- Two-way communication : Atlassian Connect add-ons can pull data and push data back using JIRA or Confluence's REST APIs, listen for events with webhooks, and recognize different users via JWT authentication.
Training/Availability
Atlassian will provide extensive training and discussion of Atlassian Connect at its upcoming eighth annual developer conference, AtlasCamp , to be held June 3-5 in Berlin, Germany. For more information, go to www.atlassian.com/AtlasCamp . Developers interested in building Atlassian Connect add-ons for public distribution or private use can access developer tutorials and documentation at connect.atlassian.com .
Newly available add-ons for JIRA and Confluence OnDemand built using Atlassian Connect include:
- Zendesk for JIRA: Seamlessly escalate Zendesk tickets to JIRA to keep customer support, developers, and product managers all in sync
- EazyBI for JIRA: A powerful business intelligence tool with drag-and-drop creation of pivot tables and charts based on JIRA data
- Canvas for Confluence and JIRA: Interactive boards help teams collaborate visually: create issues or pages, drag to organize by field attribute or label, and filter
- Harvest Time Tracking for JIRA: Integration between JIRA and the Harvest time tracking platform so users can track time on JIRA issues from within JIRA
- Ink File Picker for Confluence: Allows Confluence users to attach files to pages from over a dozen cloud storage services, including Box, Dropbox, Google Drive, and SkyDrive
- Aha! Product Roadmaps for JIRA: Create product strategy and visual roadmaps in Aha! and move epics and stories into JIRA to be developed
Developer tutorials and documentation are available at connect.atlassian.com .
About Atlassian
Atlassian products help innovators everywhere plan, build and launch great software. More than 33,000 large and small organizations – including Citigroup, eBay, Coca-Cola, Netflix and United Airlines – use Atlassian’s issue tracking, collaboration and software-development products to work smarter and deliver quality results on time. Learn more at http://atlassian.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140304005805/en/
Contact:
Atlassian
Aaron Forman, 415-701-1110 ext. 4450
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum